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Mycobacterium tuberculosisA B S T R A C T
Objective/background: The latest incidence of tuberculosis (TB) (per 100,000 people) in
Cameroon was 243.00 as of 2011. Over the past 21 years, the value for this indicator has
fluctuated between 112.00 in 1990 and 320.00 in 2003. Worldwide, this incidence has also
increased, bringing back TB as a reemerging disease. On the same note, resistance to
anti-TB drugs has increased, urging the search for new molecules.
Methods: This study was carried out to evaluate the antimycobacterial activity of six
medicinal plants on the virulent strain, H37Rv, using the microplate alamarBlue assay.
Mycobacterium tuberculosis (H37Rv strain) was incubated with decreased concentrations of
six plant extracts, ranging from 250 lg/mL to 31.25 lg/mL. After 7 days of incubation at
37 C, the effects of these plant extracts on the viability of the mycobacteria were evaluated.
For each plant extract, the minimal inhibitory concentration was determined.
Results: The results showed that the compounds MBC1, MBC24, MBC68, MBC81, MBC117,
and MBC118 were the best candidates with minimal inhibitory concentrations of 31.25,
62.5, 125, 62.5, and 125 lg/mL, respectively.
Conclusion: These results confirm and validate the traditional use of these plants to treat
respiratory diseases, which could be good sources and alternatives of plant metabolites
for anti-TB-drug development.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB) is a global pandemic caused by Mycobac-
terium tuberculosis [1,2]. Globally, there are an estimated 9.3million new cases and 13.7 million chronic active cases
responsible for 1.7 million deaths worldwide yearly. About
one-third of the world’s population is at risk to develop active
TB and contribute to the continued spread of M. tuberculosis
Fig. 1 – Leaves of Garcinia preussii.
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of central concern of public health and infectious diseases, the
last few decades have witnessed the rise of human immunod-
eficiency virus/AIDS, an immunosuppressive illness that
amplifies the infectivity of the tubercle bacillus and catalyzes
its conversion from latent to active infection [6]. Furthermore,
the emergence of M. tuberculosis strains resistant to conven-
tional first-line and second-line antitubercular treatment is
particularly worrisome [7,8], since no new anti-TB drugs have
been introduced into themarket since 1967.Moreover, up to 50
million people are infected with drug-resistant forms of TB
with about 500,000 cases of multidrug-resistant TB a year
worldwide [9]. Even though there are currently new lead com-
pounds being characterized for TB treatment [10,11], they are
challenged by poor accessibility, high costs, long treatment
regimen, and low adherence owing to the toxicity of second-
line drugs. The newly commercialized drug is likely to be
exhausted with the emerging resistance, emphasizing the
imperative continuous search, identification, and characteri-
zation of more compounds for anti-TB drugs.
Medicinal plants have been used for centuries as nonex-
haustive sources of metabolites for drug development and
as an alternative remedy for treating human diseases, as they
contain numerous active constituents of therapeutic value
[12–15]. Rational chemistry, while essential to the develop-
ment of many modern pharmaceuticals, often serves better
to refine the chemical blueprints isolated from natural pro-
duct screens than to devise entirely new molecular back-
bones. The enormous diversity of plant-derived compounds
therefore makes them one of the most promising reservoirs
of potentially novel anti-TB molecules. Cameroon is
renowned for its rich and uncharacterized biodiversity [16],
and Cameroonian medicinal plants are frequently used to
treat diseases as a means of reducing reliance on expensive
imported and/or chemical drugs. Such plants should be iden-
tified and screened on the basis of traditional knowledge for
efficacy in the treatment of TB.
This work reports on the in vitro anti-TB evaluation of
medicinal plants identified during an ethnobotanical survey
carried out in Kala at the Department of ‘‘Me´fou-et-Akono”/C
entre Region and in Dschang at the Menoua Department/West
Region. This survey investigated on medicinal plants used by
traditional healers to treat cough and pulmonary diseases.
Materials and methods
Plant collection and conditioning
Plants (bark, roots, and stalk) were collected based on the
information obtained from traditional healers from Kala at
the Department of ‘‘Me´fou-et-Akono”/Centre Region and in
Dschang at the Menoua Department/West Region of
Cameroon. In Cameroon, generally, most people rely on tradi-
tional healers for their primary health care. These traditional
healers used plants to treat persisting cough and chest pain.
They have inherited the knowledge from their parents, grand-
parents, and ancestors.
The collected plants were identified at the National
Herbarium of Yaounde´, where voucher-specimen numberswere obtained. Figs. 1 and 2 are photographs of two of the
plants used (Garcinia preussei and Acanthus montanus). The
plant material was dried and ground into coarse or fine pow-
der depending on their texture.
Preparation of plant extract
Crude extracts of plant parts were prepared as follows:
1. For hot extraction, 40 g of the powdered bark or stalk was
weighed and put into the extraction thimble on the Soxh-
let to which 250 mL of the solvent was added. The various
solvents used were methanol, hexane, and ethyl acetate.
The Soxhlet was switched on and extraction was carried
out for 2 h and 30 min. The solvent was removed from
the extract by evaporation on a rotavapor.
2. For cold extraction, 100 g of powdered roots or stalk was
weighed and added into 500 mL of the solvent. Extraction
was carried out at room temperature with frequent shak-
ing for 48 h. The filtrates were evaporated to dryness using
the rotavapor.
The obtained crude extracts were thus stored at 4 C for
subsequent work. The phytochemical screening of the plant
extracts was carried out by themethod described by Harborne
[17].
In vitro anti-TB screening
M. tuberculosis culture preparation
The M. tuberculosis reference strain, H37Rv, was used. Ten
milliliters of Middlebrook 7H9 broth supplemented with 10%
oleic acid–albumin–dextrose–catalase and 0.2% of glycerol
culture was inoculated with 0.4–0.6 mL of freezer stock of
H37Rv in a 50 mL conical tube. The culture was grown to
mid-log phase on the wheel at 37 C, until OD600 = 0.4–0.8.
Using 7H9 broth without Tween 80, the culture was diluted
to OD600 = 0.001. This resulted in a culturewith approximately
105 CFU/mL. Then, 100 lL of this culture was used to set up
the assay plates, with each well containing 104 CFU.
Antimycobacterial-activity tests
The antimycobacterial activity of the plant crude extracts
was tested using the microplate alamarBlue assay [18,19].
Fig. 2 – Stalk and leaves of Acanthus montanus.
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the alamarBlue reagent as an indicator of cellular viability.
Working solutions of the tested extracts were diluted in
Middlebrook 7H9 broth supplemented with oleic acid–
albumin–dextrose–catalase to obtain the final sample
concentrations that ranged from 250 lg/mL to 31.25 lg/mL.
Isoniazid was dissolved in dimethyl sulfoxide and used as
a positive control drug at 1.28 lg/mL as the starting concen-
tration, and extracts/drug-free medium with strain suspen-
sions were used as the negative control. One hundred
microliter of 7H9 broth were added into all wells of the
96-well plate, and 100 lL of the compounds/extracts was
introduced to the wells in the first row (A) and mixed thor-
oughly. The sample mixture (100 lL) was removed from wells
of row A to perform a twofold serial dilution down the rows
(B–H). The last 100 lL was discarded. Then, 100 lL of the
inoculum was introduced into the corresponding wells.
The final volume in each well was 200 lL. Each extract con-
centration was assayed in duplicate. Each microplate was
then sealed with the optical sealing tape and incubated for
7 days at 37 C in normal atmosphere. After the incubation
period, 32.5 lL of alamarBlue was added to each well. The
plates were then reincubated for 16–18 h at 37 C in the dark.
The experimental results were computerized using the BMG,
Leicester, United Kingdom OPTIMA microplate reader at
544ex/590em for data analysis.
The minimal-inhibitory-concentration (MIC) results were
presented as mean value. The lowest concentration that
resulted to 90% inhibition was defined as the MIC. The MIC
values determined by this method were cross-checked using
the broth-dilution methods. A blue color in the well was
scored as ‘‘no mycobacterial growth,” and a pink color was
scored as ‘‘growth occurrence” [20,21].Results
Plants collected
Table 1 presents the identification of the six studied plants, by
scientific and family names, traditional usage, and voucher-
specimen number. These plants belong to the following
families: Annonaceae, Vitaceae, Rubiaceae, Urticaceae,
Lauraceae, and Acanthaceae.
Crude-extract preparation
Six different crude extracts were prepared with different sol-
vents of extraction. The plant parts analyzed, the solvents
used, and the yields of extraction are presented in Table 2.Antimycobacterial activity
The antimycobacterial activity of the plant crude extracts has
been evaluated on the virulent strain H37Rv at the highest
concentration of 250 lg/mL. The six tested extracts, namely,
A. montanus, Beilschmiedia obscura, Cissus petiolata, Enantia chlo-
rantha, Urera repens, and Garcinia preussii, were active against
M. tuberculosis with MICs ranging from 31.25 lg/mL to
250 lg/mL. These results are summarized in Table 3.
The most active anti-TB effect was obtained from the
methanolic extract of B. obscura with an MIC of 31.25 lg/mL
that inhibits the growth of M. tuberculosis at 96.2%. The
methanolic extract of A. montanus and U. repens each exhib-
ited an antimycobacterial activity with an MIC of 62.5 lg/mL
and a percentage of growth inhibition of 95.06% and 98.4%,
respectively.
Phytochemical screening of the plant extracts
The screens identified various compounds from the plant
extracts. These compounds include phenols, sterols, sapo-
nins, flavonoids, and glycosides. These results are presented
in Table 4 for each plant.Discussion
Beilschmiedia species are known to produce many types of
phytochemicals [22–24] with various biological activities.
Besides, Fankam, Kuiate, and Kuete [25] worked on fruits of
B. obscura, and found that they were highly active against a
panel of Gram-negative bacteria.
Plants from the Acanthaceae family are widely used tradi-
tionally for the treatment of various ailments, such as infec-
tious diseases [26,27]. The antimycobacterial activity
observed from Acanthus montanus corroborated with the study
of Ikezu, Ajiwe, Ilozue, and Chukwukanne [28], who worked
on the leaves of A. montanus. They found that, in comparison
with the activity of some standard antibiotics, the leaves of A.
montanus were more active against Gram-negative and
Gram-positive bacteria.
The roots ofG. preusseidisplayed anMICof 125 lg/mLon the
virulent strain H37Rv. The biological activity of compounds









MBC1 Enantia chlorantha Annonaceae Malaria, body pains, gastrointestinal troubles, cough 28724/SRF/Cam
MBC17 Cissus petiolata Vitaceae Asthma, cough, hemorrhoids, gonorrhea 9163 SRF Cam
MBC24 Beilschmiedia obscura Lauraceae Friction on localized pains, respiratory problems 1004/SRFK
MBC68 Urera repens Urticaceae Abscess, headache, purge, asthma 7450/SRF/Cam
MBC117 Acanthus montanus Acanthaceae Fever, furuncles, cancer, ulcer, cough 2127/SRFK
MBC118 Garcinia preussei Clusiaceae Stomachaches, toothaches, chewstick, cough 19325/SRF/Cam
Table 2 – Solvents used and yield of extraction.
Plant code Scientific name Part used Extraction solvent Yield (mg/100 g)
MBC1 Enantia chlorantha Bark CH3OH 1.70
Hot extraction
MBC17 Cissus petiolata Stalk CH3OH 0.24
Hot extraction
MBC24 Beilschmiedia obscura Roots CH3COOC2H5 0.70
Cold extraction
MBC68 Urera repens Stalk CH3OH 0.66
Hot extraction
MBC117 Acanthus montanus Stalk Hexane 0.72
MBC118 Garcinia preussei Roots Hexane/ethyl acetate 50:50 1.00
Table 3 – Antimycobacterial activity of the six plant extracts.
Plant code Name of the plant Part used MIC (lg/mL) Percentage of inhibition (%)
MBC1 Enantia chlorantha Bark 250 91.9
MBC17 Cissus petiolata Stalk 250 97.9
MBC24 Beilschmiedia obscura Roots 31.25 96.2
MBC68 Urera repens Stalk 62.5 98.4
MBC117 Acanthus montanus Stalk 62.5 95.06
MBC118 Garcinia preussei Roots 125 96.7
MIC = minimal inhibitory concentration.
Table 4 – Results of the phytochemical tests done on four of the six plant extracts.
Beilschmiedia obscura Urera repens Acanthus montanus Garcinia preussei
Phenols +   
Triterpenes    
Sterols +  +++ +++
Tannins + + + +
Saponins    +
Flavonoids +++ ++ +++ +++
Alkaloids  +  
Lipids + + + +
Glycosides + + ++ 
Sugars  + + 
The symbol ‘‘+” means ‘‘present,” while the symbol ‘‘” means ‘‘absent”.
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nosa, Staphylococcus aureus, and Enterococcus faecalis has
already been evaluated and shows interesting activities [29].
Kaikabo and Eloff [30] isolated two biflavonoids from Garcinia,
and found that they were active against fast-growing andnonpathogenicMycobacterium smegmatis, andhad agoodactiv-
ity against nosocomial bacteria.
Although no antibacterial activity has yet been evaluated
on C. petiolata, a plant belonging to the Vitaceae family,
Garima, Saurabh, and Nagori [31] did an overview on the
310 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 3 0 6 –3 1 1pharmacological and therapeutic activity of Cissus quadrangu-
laris, a plant from the same family. They reported that two
asymmetrical tetracyclic triterpenoids and calcium were
identified as its major constituents, and that it possesses
antibacterial and antifungal activities [32–35]. Moreover, the
phytochemical study of the aerial part of C. quadrangularis
done by Ruskin et al. [15] showed the presence of alkaloids,
tannins, and flavonoids. These wide variety of phytochemical
compounds could justify the antimycobacterial activity
observed with C. petiolata.
The investigation of E. chlorantha stem barks showed that
they contained a large quantity of phenols, alkaloids, sapo-
nins, flavonoids, and glycosides [36,37]. In addition, several
reports in the literature indicate a wide variety of pharmaco-
logical activities of this plant [38,39]. This can justify the
observed antimycobacterial activity.
The stalk of U. repens showed an interesting activity with
an MIC of 62.5 lg/mL. To the best of our knowledge, the
antimycobacterial activity of this plant is being reported here
for the first time. Nevertheless, according to Gindri et al. [40],
the leaves of Urera baccifera, a plant from the same genus
Urera, inhibited the growth of Klebsiella pneumoniae, a
Gram-negative bacterium.
It is worth pointing out that the activities showed from the
plants studied are those from crude and unpurified, thus non-
concentrated, compounds. It is expected that fractionation of
these crude extracts will improve the MIC observed.
Conclusion
The obtained results confirm and validate the traditional use
of some of these plants, which could be good sources and
alternative of metabolites for anti-TB-drug development.
These encouraging results prompted us to pursue the evalua-
tion of the most active extracts. Therefore, fractionation and
further phytochemical and pharmacological studies of these
plants are evidently worthy, and our group is focusing on this
effort.
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